Biosimilars Market to reach USD 193.2 Billion by 2035 at 17.0% CAGR

Biosimilars Market to Surge from USD 40.2 Billion in 2025 to USD 193.2 Bn by 2035— Patent Expirations of Blockbuster Biologics, Expanding Regulatory Pathways

NY, CA, UNITED STATES, September 7, 2026 /EINPresswire.com/ -- As per Market Research Future, the global Biosimilars Market size is projected to reach USD 193.2 Billion by 2035 from USD 40.2 Billion in 2025, at a CAGR of 17.0% during the forecast period 2025–2035.

The extraordinary 17.0% CAGR is propelled by three converging forces: the wave of patent expirations for blockbuster biologics, with over USD 200 billion worth of innovator biologics set to go off-patent by 2030, creating a massive opportunity for biosimilar entry; maturing regulatory pathways and expanding interchangeability designations, with the FDA having approved 96 biosimilars by the end of 2025, 25 of them designated interchangeable, permitting pharmacy-level substitution; and the escalating demand for cost-effective biologic therapies, as healthcare systems worldwide face unsustainable spending on biologics and recognize biosimilars as a proven mechanism to expand patient access while containing costs.

Global pharmaceutical companies and regulatory agencies are amplifying this momentum. The FDA approved 18 biosimilars in 2025 alone across oncology, immunology, endocrinology, and ophthalmology. The European Medicines Agency, which approved the first biosimilar in 2006, continues to lead in adoption, with Europe holding a significant share of the global market. Asia-Pacific is emerging as the fastest-growing region with a projected CAGR exceeding 20%, driven by South Korean giants Samsung Bioepis and Celltrion, India's robust biosimilar industry, and China's regulatory reforms. Together, these forces are creating the regulatory infrastructure, manufacturing capacity, and commercial demand on which the Biosimilars Market depends.

Request A Free Sample:
https://www.marketresearchfuture.com/sample_request/1329

Key Market Trends & Growth Drivers

Patent Expirations of Blockbuster Biologics

The surge in market value is primarily driven by patent expirations of major biologics. Over USD 200 billion worth of innovator biologics are set to go off-patent by 2030, with biosimilars positioned to capture significant market share. The most anticipated upcoming opportunity is Keytruda (pembrolizumab), the world's top-selling immunotherapy with over USD 31 billion in 2025 sales, as it approaches its 2028 patent expiry. Multiple drugmakers are already gearing up to enter the market with lower-cost biosimilar alternatives.

Maturing Regulatory Pathways and Interchangeability

Strengthening regulatory frameworks are accelerating biosimilar approvals and clinical acceptance. By the end of 2025, the FDA had approved 96 biosimilars, 25 of them designated interchangeable. Interchangeable designation permits pharmacy-level substitution without prescriber intervention where state law allows. The FDA's modernization of the biosimilar pathway is reducing barriers to entry by prioritizing advanced analytical characterization over repetitive comparative clinical trials, lowering development costs and shortening time to market.

Rising Demand for Affordable Biologic Therapies

Rising healthcare costs, increasing chronic disease prevalence, and growing demand for affordable biologic therapies are accelerating biosimilar adoption worldwide. Biosimilars, priced typically 40-50% lower than biologics, offer affordable alternatives for treating non-communicable diseases. In mature markets, next-generation biosimilars are achieving faster and broader adoption—bevacizumab biosimilars accounted for 93% of the biologic volume share in Europe in 2024.

Expanding Asia-Pacific Manufacturing and Supply Chains

Growth in low-cost, large-scale biomanufacturing, particularly across Asia-Pacific, is broadening global access and supporting margins. Companies such as Celltrion, Samsung Bioepis, Biocon Biologics, and Shanghai Henlius Biotech operate substantial capacity and increasingly vertically integrated supply chains. South Korea has emerged as a leader, allocating 35% of its medical research budget in 2012 to support local pharmaceutical companies, with more than 70 biosimilars approved as of 2024. India has over 100 approved biosimilars, with more than 100 biopharma companies working on various platforms.

Ask for Customization:
https://www.marketresearchfuture.com/ask_for_customize/1329

Market Segment Insights

BY PRODUCT TYPE

Monoclonal Antibodies: Dominant segment, capturing the largest share due to their widespread use in cancer and autoimmune disease treatment. Monoclonal antibody biosimilars for infliximab, rituximab, trastuzumab, and adalimumab are driving strong commercial demand.

Recombinant Non-Glycosylated Proteins: Fastest-growing segment, including human growth hormone, granulocyte colony-stimulating factor (filgrastim), insulin, and interferons.

Recombinant Glycosylated Proteins: Significant segment generating substantial revenue in 2025.

BY THERAPEUTIC AREA

Oncology: Largest segment, commanding the largest slice of reimbursement budgets. Oncology biosimilars like bevacizumab and trastuzumab achieved volume market shares of 82% and 78%, respectively, within three years of US launch.

Autoimmune and Inflammatory Diseases: Fastest-growing segment, driven by upcoming biosimilar launches for adalimumab, ustekinumab, and other immunology blockbusters.

Ophthalmology: Projected to grow at a strong CAGR through 2035, driven by biosimilars for ranibizumab and aflibercept.

BY REGION

Europe: Current market leader, benefiting from early adoption (first biosimilar approved in 2006), supportive regulations, and favorable government policies.

Asia-Pacific: Fastest-growing region, catalyzed by South Korean giants Samsung Bioepis and Celltrion, China's regulatory reforms, and India's generics heritage.

North America: Largest absolute revenue potential, supported by 96 FDA approvals and the Inflation Reduction Act's reimbursement incentives for biosimilars.

Read Detailed Insights:
https://www.marketresearchfuture.com/reports/biosimilars-market-1329

Regional Outlook

Europe — Market Leader

Europe leads the global biosimilars market, reflecting its pioneering 2006 regulatory path and coordinated procurement policies. Many EU member states have instituted gain-sharing schemes, channeling savings back to hospital budgets, which encourages prescriber engagement. Germany, France, Italy, Spain, and the UK continue to drive adoption across multiple therapeutic areas. The European Medicines Agency's streamlined approval pathways and robust pharmacovigilance frameworks have improved physician confidence and enabled broader patient access.

North America — Largest Absolute Revenue Potential

North America, dominated by the United States, lags Europe in penetration yet offers the largest absolute revenue potential, supported by 96 FDA approvals and 25 interchangeable designations as of 2025. Medicare payment reforms embedded in the Inflation Reduction Act (IRA) are realigning incentives toward rapid biosimilar switching in public programs, with projected U.S. savings of USD 181 billion over five years. The IRA also increased reimbursement for biosimilars to Average Selling Price (ASP) + 8% of the reference product's ASP, compared to 6% for originators, incentivizing physicians to prescribe biosimilars.

Asia-Pacific — Fastest-Growing Region

Asia-Pacific is the fastest-growing territory, catalyzed by South Korean giants Samsung Bioepis and Celltrion, China's regulatory reforms, and India's generics heritage. South Korea leads in biosimilar manufacturing, with more than 70 biosimilars approved as of 2024. China has approved over 20 domestically developed biosimilars, with the oncology and immunology biosimilar market alone achieving substantial sales. India has over 100 approved biosimilars, with more than 100 biopharma companies working on various platforms.

Emerging Markets — Significant Opportunity

Emerging markets represent a significant growth opportunity for biosimilars. Biocon Biologics has secured leading positions by volume in several countries, including 58% share for bevacizumab in South Africa, 85% for rh-insulin in Mexico, and 40% for trastuzumab in Brazil. These markets are rapidly adopting biosimilars as governments prioritize affordable biologic access.

Competitive Landscape

The Biosimilars Market is characterized by a dynamic competitive landscape, with major players actively pursuing strategies emphasizing innovation, regional expansion, and digital transformation.

KEY COMPANIES:

Celltrion (South Korea)
Samsung Bioepis (South Korea)
Biocon Biologics (India)
Sandoz Group AG (Switzerland)
Pfizer Inc. (US)
Amgen Inc. (US)
Dr. Reddy's Laboratories (India)
Cipla (India)
Zydus Lifesciences (India)
Recent Industry Developments:

Samsung Bioepis: Developing SB27, a pembrolizumab biosimilar, with global Phase 3 trials initiated in April 2024.
Cipla (September 2026): In-licensed exclusive rights to Qilu Pharmaceutical's QL2107 (Keytruda biosimilar) for the US market.
Zydus Lifesciences: Partnered with Formycon AG to market a Keytruda biosimilar.
Future Outlook: 2025–2035

The Biosimilars Market is projected to reach USD 193.2 Billion by 2035, growing at a CAGR of 17.0%, driven by patent expirations, regulatory modernization, and rising demand for affordable biologic therapies.

New opportunities lie in:

Checkpoint Inhibitor Biosimilars: The most anticipated upcoming opportunity is Keytruda (pembrolizumab), with over USD 31 billion in 2025 sales, as it approaches its 2028 patent expiry. Multiple drugmakers are already advancing pipelines.
GLP-1 Biosimilars: With semaglutide patents expected to expire in China by 2026 and globally by 2031, biosimilar manufacturers are positioning themselves to enter one of the fastest-growing therapeutic categories.
Biosimilars as Foundational Infrastructure for Sustainable Biologic Therapy: By introducing competition into previously monopolized biologic markets, they free resources for innovation and broaden patient access to advanced therapies.
Emerging-Market Expansion: As healthcare systems worldwide face rising biologic spending, biosimilars provide a proven mechanism to expand access while containing cost.
By 2035, the Biosimilars Market is expected to achieve substantial growth, solidifying its critical role in expanding patient access to biologic therapies and creating a more sustainable healthcare ecosystem.

More Related Research Insights:

https://www.marketresearchfuture.com/ja/reports/beauty-devices-market-562

https://www.marketresearchfuture.com/fr/reports/fibrotic-diseases-treatment-market-37026

https://www.marketresearchfuture.com/ja/reports/fibrotic-diseases-treatment-market-37026

https://www.marketresearchfuture.com/de/reports/fibrotic-diseases-treatment-market-37026

https://www.marketresearchfuture.com/es/reports/fibrotic-diseases-treatment-market-37026

https://www.marketresearchfuture.com/zh-cn/reports/fibrotic-diseases-treatment-market-37026

https://www.marketresearchfuture.com/ko/reports/fibrotic-diseases-treatment-market-37026

https://www.marketresearchfuture.com/fr/reports/microneedle-patche-market-38683

https://www.marketresearchfuture.com/ja/reports/microneedle-patche-market-38683

https://www.marketresearchfuture.com/de/reports/microneedle-patche-market-38683

Market Research Future
Market Research Future
+1 855-661-4441
email us here